ArticleMolecules (Basel, Switzerland)2025
Preparation, Digestion, and Storage of Microencapsulated Nervonic Acid-Enriched Structured Phosphatidylcholine.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study focuses on the encapsulation of nervonic acid-enriched structured phospholipid (NA-enriched SPL) by analysing its physical and chemical properties. Wall materials for encapsulation were initially screened, with whey protein isolate and maltodextrin exhibiting the most favourable characteristics. Optimisation of encapsulation parameters determined that a core-to-wall ratio of 1:3 provided the highest physical stability. Encapsulated samples underwent in vitro digestion, where MC-FD exhibited the highest digestibility (79.54%), followed by CV-E (72.1%) and NA-enriched SPL (29.82%). Storage stability was assessed over 90 days at 4 °C, 25 °C, and 45 °C by monitoring particle size, zeta potential, polydispersity index, microscopy, fatty acid composition, and primary and secondary lipid oxidation. MC-FD demonstrated superior stability, maintaining its physical and chemical properties, particularly at 4 °C. In contrast, CV-E showed the lowest physical stability, with significant changes in appearance and increased particle size at elevated temperatures (25 °C and 45 °C).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.